We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03164447
Recruitment Status : Not yet recruiting
First Posted : May 23, 2017
Last Update Posted : May 13, 2022
Information provided by (Responsible Party):
United BioPharma

Brief Summary:
This is a Phase 2, multi-center study, designed to evaluate the efficacy, safety, and tolerability of UB-421 in conjunction with a failing existing ART regimen for 1 week and optimized background therapy (OBT) for 24 weeks, respectively.

Condition or disease Intervention/treatment Phase
HIV-1 Infection Biological: UB-421 Drug: Optimized background therapy (OBT) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Estimated Study Start Date : December 2022
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Multi-Drug Resistant Biological: UB-421
Monoclonal antibody by IV infusion

Drug: Optimized background therapy (OBT)
The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.

Primary Outcome Measures :
  1. Effectiveness by Viral Load Log10 Change from Baseline [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events [ Time Frame: 35 weeks ]
  2. Peak concentration of UB-421 [ Time Frame: 35 weeks ]
  3. Trough concentration of UB-421 [ Time Frame: 35 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females, age ≥18 years;
  2. HIV-1 seropositive, with documented HIV-1 infection by official, signed, written history (eg. Laboratory report);
  3. Receiving a combination antiretroviral therapy (cART) (failing regimen) for at least 8 weeks before Screening and are willing to continue on the failing regimen during the Screening Phase and up to Day 14 of the Treatment Phase, OR have failed in the past 8 weeks of Screening and are off therapy and are willing to stay off therapy until Day 14 of the Treatment Phase;
  4. Plasma HIV-1 RNA ≥ 1000 copies/mL at the Screening Visit and documented detectable viral load (HIV-1 RNA >200 copies/ml) within the last 3 months prior to the Screening Visit;
  5. Highly treatment-experienced HIV-infected patients with documented genotypic and/or phenotypic resistance to at least one ARV drug within three or more drug classes of antiretroviral medications and have difficulty in constructing a viable suppressive regimen.
  6. Have full viral sensitivity/susceptibility to at least one approved antiretroviral agent, other than UB-421, as determined by genotypic and/or phenotypic ARV drug resistance tests at screening, and such agent can be used as a component of OBT;
  7. Be willing to remain on treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure;
  8. Have a life expectancy that is > 9 months;
  9. Laboratory values at Screening of:

    1. Absolute neutrophil count (ANC) ≥ 750/mm3;
    2. Hemoglobin (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female);
    3. Platelets ≥ 75,000 /mm3;
    4. Serum alanine transaminase (SGPT/ALT) < 2.5 x upper limit of normal (ULN);
    5. Serum aspartate transaminase (SGOT/AST) < 2.5 x ULN;
    6. Bilirubin (total) < 2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease; and
    7. Creatinine ≤ 1.5 x ULN
  10. Clinically normal resting 12-lead electrocardiogram (ECG) at the Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.
  11. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants,injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and
  12. Willing and able to participate in all aspects of the study, including use of IV medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion Criteria:

  1. Any currently active AIDS-defining illness per Category C conditions according to the Center for Disease Control (CDC) Classification System for HIV Infection, with the following exceptions: local cutaneous Kaposi's sarcoma, wasting syndrome due to HIV or any other AIDS-defining illness for which no therapeutic treatment is required OR the required treatment is not included in the list of prohibited medications;
  2. Subjects with baseline liver disease including active Hepatitis B or C infection or any other active infection secondary to HIV requiring acute therapy;
  3. Subjects with baseline CD4 counts < 350 cells/mm^3.
  4. Any ≥ Grade 3 laboratory abnormality according to the division of AIDS grading scale;
  5. Unexplained fever or clinically significant illness within 2 weeks prior to the first dose of study drug;
  6. Any vaccination within 2 weeks prior to the first dose of study drug;
  7. Any immunomodulating therapy (excluding pre-medication steroid) or systemic chemotherapy within 4 weeks prior to the Screening Visit;
  8. Any radiation therapy within 4 weeks prior to the Screening Visit;
  9. Any previous exposure to monoclonal antibody for the treatment of HIV within 12 weeks prior to the Screening Visit (excluding ibalizumab);
  10. Participation in an experimental drug trial(s) within 4 weeks prior to the Screening Visit;
  11. Any prior exposure to UB-421;
  12. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study; and
  13. Any significant diseases (other than HIV-1 infection) or clinically significant findings that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03164447

Layout table for location contacts
Contact: Zhonghao Shi +886-3-668-4800 ext 3641 Zhonghao.Shi@unitedbiopharma.com

Sponsors and Collaborators
United BioPharma
Layout table for additonal information
Responsible Party: United BioPharma
ClinicalTrials.gov Identifier: NCT03164447    
Other Study ID Numbers: UBP-A205-HIV
First Posted: May 23, 2017    Key Record Dates
Last Update Posted: May 13, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
HIV Infections
Disease Attributes
Pathologic Processes
Blood-Borne Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents